BioSpace News Archive

NeoSpectra by Si-Ware today announced the release of the first-of-its-kind marketplace of near-infrared (NIR) calibration models with the launch of the NeoSpectra LabStore.

Cytokinetics, Incorporated presented new data on the reduction and withdrawal of background standard of care medical therapy in patients treated with aficamten in REDWOOD-HCM OLE in a Late Breaking Clinical Trials session at the 2022 HCM Society Scientific Sessions, the inaugural scientific sessions of this newly launched professional medical society, held in National Harbor, MD.

The U.S. Food and Drug Administration published guidance that will help provide a pathway for infant formulas operating under enforcement discretion in the U.S. to remain on the market.

Mentice AB a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2023 has been appointed.

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time.

AB Science SA reports its revenues for the first half of 2022 and provides an update on its activities.

Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus, announced that it has reached its initial goal to raise at least $5M in a Series Seed round of financing.

A first-of-its-kind study published in AACC’s Clinical Chemistry journal shows that a novel drug test detects a new class of synthetic cannabinoids called OXIZIDs.

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 8,333 new ordinary shares of £0.10 each in the Company.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced results from exploratory endpoints and additional analyses of prespecified patient subgroups for the primary and secondary endpoints in the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy.